Efficacy of ertapenem in the treatment of serious infections caused ...

Ertapenem therapy was as effective as either piperacillin-tazobactam or ceftriaxone for serious infections caused by Enterobacteriaceae.

Ertapenem therapy was as effective as either piperacillin–tazobactam or ceftriaxone for serious infections caused by Enterobacteriaceae.

Efficacy of ertapenem in the treatment of serious infections caused ...

for serious infections caused by Enterobacteriaceae. Keywords: ertapenem, Enterobacteriaceae, Escherichia coli, intra-abdominal infection, skin infection.

Efficacy of Ertapenem for Treatment of Bloodstream Infections ...

Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and ...

Clinical efficacy of ertapenem vs. other carbapenems for the ...

Ertapenem could be as effective as other carbapenems in the treatment of patients with ESBL-producing Enterobacterales infections.

Efficacy of ertapenem in the treatment of serious infections caused ...

Among evaluable patients with deep tissue (intra-abdominal, skin and pelvic) infections, the combined clinical cure rates were 84.8% (223 of 263) for ertapenem ...

Efficacy and safety of de-escalation therapy to ertapenem for ...

Carbapenem antibiotics are considered the treatment of choice for serious infections caused by ESBL-producing Enterobacteriaceae [10]. Many ...

Effectiveness of ertapenem for treatment of infections in children

Ertapenem had similar treatment success rates with β-lactam antibiotics [relative risk (RR) = 1.08, 95% CI: 0.99–1.19]. In a subgroup analysis, ...

The Clinical Efficacy and Safety of Ertapenem for the Treatment of ...

Ertapenem is a newer carbapenem with the advantage of once-daily dosing and is highly effective for treating UTIs caused by ESBL-producing microorganisms.

Ertapenem - an overview | ScienceDirect Topics

A 1 g once a day of Ertapenem was highly effective for treatment of adults with serious infections caused by Enterobacteriaceae. ... efficacy of IV ertapenem at ( ...

Ertapenem versus piperacillin/tazobactam for the treatment of ...

Ertapenem, a new carbapenem with a favorable pharmacokinetic profile, has been approved for the treatment of complicated intra-abdominal ...

Outpatient parenteral antimicrobial therapy with carbapenems

Ertapenem monotherapy, once daily, achieved an 81% clinical cure rate for urinary tract infections. Additionally, subcutaneous ertapenem in OPAT ...

Effectiveness of ertapenem for treatment of infections in children

Children with infectious diseases are commonly encountered in primary care settings (4). Perforated appendicitis (5–7), severe community- ...

Efficacy and safety of de-escalation therapy to ertapenem for ...

Carbapenem antibiotics are considered the treatment of choice for serious infections caused by ESBL-producing. Enterobacteriaceae [10]. Many studies have ...

A study evaluating the efficacy, safety, and tolerability of ertapenem ...

It is suggested that ertapenem and ceftriaxone therapy have similar efficacy and safety in hospitalized patients with community-acquired pneumonia.

Ertapenem as effective as other antibacterials in treating intra ...

Ertapenem has a role in the treatment of community-acquired pneumonia associated with typical respiratory pathogens and is of particular value ...

Efficacy of Ertapenem for Treatment of Bloodstream Infections ...

BazazR ChapmanAL WinstanleyTG. 2010. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum ...

(PDF) Efficacy of Ertapenem for Treatment of Bloodstream Infections ...

Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and ...

Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in ...

Overall, eravacycline demonstrated noninferiority to ertapenem for the treatment of patients with cIAI, and both study drugs were well tolerated.

INVANZ - accessdata.fda.gov

moderate to severe infections caused by susceptible strains of the ... treatment groups. 16. Page 17. : INVANZ: Complicated Skin and Skin Structure Infections.